OLIPASS CORPORATION Logo

OLIPASS CORPORATION

Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.

244460 | KO

Overview

Corporate Details

ISIN(s):
KR7244460002
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 동백중앙로16번길 16-4 에이스동백타워1동 20층, 용인시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

OLIPASS CORPORATION is a biotechnology company focused on the research and development of RNA therapeutics. The company's core technology is its proprietary OliPass Peptide Nucleic Acid (OPNA) platform. This platform utilizes a modified PNA with covalently attached cationic lipid groups, which significantly enhances cell permeability. OPNA is designed to induce exon skipping by specifically binding to target pre-mRNA within the cell nucleus. This mechanism enables the development of a pipeline of novel therapeutic drug candidates for various diseases. The company's vision is to become a leading global R&D company in the field of RNA therapeutics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Korean 11.7 KB
2025-09-15 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Korean 11.3 KB
2025-09-15 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Korean 10.7 KB
2025-09-12 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 16.1 KB
2025-09-12 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 63.1 KB
2025-09-10 00:00
Delisting Announcement
기타시장안내 (상장폐지 관련 이의신청서 접수)
Korean 2.9 KB
2025-09-08 00:00
M&A Activity
기타경영사항(자율공시) (공개매각을 위한 주간사계약 체결의 건)
Korean 5.5 KB
2025-08-20 00:00
Delisting Announcement
기타시장안내 (기업심사위원회 개최 결과 안내)
Korean 3.3 KB
2025-08-20 00:00
Delisting Announcement
주권매매거래정지기간변경 (상장폐지 사유 발생)
Korean 5.2 KB
2025-08-18 00:00
Regulatory News Service
불성실공시법인지정 (공시번복 2건)
Korean 7.6 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 12.2 KB
2025-08-14 00:00
Earnings Release
반기또는분기매출액미달사실발생
Korean 5.5 KB
2025-08-14 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 사유추가 안내)
Korean 2.9 KB
2025-08-13 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 11.2 KB

Automate Your Workflow. Get a real-time feed of all OLIPASS CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OLIPASS CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OLIPASS CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France
OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium
OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan
4766
Passage BIO, Inc. Logo
Developing genetic medicines for severe CNS and neurodegenerative disorders.
United States of America
PASG
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway
PCIB
PC İLETİŞİM VE MEDYA HİZMETLERİ SANAYİ TİCARET A.Ş. Logo
Integrated media group providing data-driven advertising and media solutions for global brands.
Türkiye
PCILT
PDS Biotechnology Corp Logo
Developing T-cell activating immunotherapies for cancer and infectious diseases.
United States of America
PDSB
Peers Co.,Ltd. Logo
Accelerating tech adoption with consulting, HR services, and proprietary IT/AI solutions.
Japan
7066
PepGen Inc. Logo
Biotech using an EDO platform to treat genetic neuromuscular & neurological diseases.
United States of America
PEPG
PeptiDream Inc. Logo
Discovers peptide therapeutics via a proprietary platform and markets radiopharmaceuticals.
Japan
4587

Talk to a Data Expert

Have a question? We'll get back to you promptly.